Publication | Closed Access

Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study

OncologyPlatinum-refractory Ovarian CancerMedicineOral EtoposideGynecologyCancer TreatmentPhase 2PharmacologyMolecular OncologyEndocrine-related CancerOvarian Cancer